Get the Stockscreener App
0.7726
0.82%
-0.0076
Mira Pharmaceuticals Inc stock is traded at $0.7726, with a volume of 52,369.
It is down -0.82% in the last 24 hours and down -19.39% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$0.7802
Open:
$0.8
24h Volume:
52,369
Relative Volume:
0.52
Market Cap:
$32.94M
Revenue:
-
Net Income/Loss:
$-31.37M
P/E Ratio:
-0.5373
EPS:
-1.438
Net Cash Flow:
$-4.23M
1W Performance:
+0.86%
1M Performance:
-19.39%
6M Performance:
-38.10%
1Y Performance:
-48.41%
1-Day Range:
$0.7738
$0.81
1-Week Range:
$0.7383
$0.825
52-Week Range:
$0.60
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.7838 | 32.79M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,188.23 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.70 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.56 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.89 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.14 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com South Africa
MIRA's obesity candidate shows rapid absorption in 7-day dog study - stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Asianet Newsable
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1 - TipRanks
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice - TipRanks
Mira advances MIRA-55 and SKNY-1 - bioworld.com
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies - GlobeNewswire
MIRA Pharmaceuticals completes toxicology studies for two candidates By Investing.com - Investing.com Nigeria
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Income Statement - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo
MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan
MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
MIRA Pharmaceuticals Company Profile & Introduction - Moomoo
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et
What's going on with MIRA Pharma stock Tuesday? - MSN
MIRAMira Pharmaceuticals Inc Options - Finviz
MIRA Q3 2025 Earnings: Loss Narrows as EPS Surprises to the Upside, but Stock SlipsEarnings Revision Upgrade - dars.gov.et
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
2.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):